Last reviewed · How we verify
Intravesical Gemcitabine and Docetaxel — Competitive Intelligence Brief
phase 2
Small molecule
Live · refreshed every 30 min
Target snapshot
Intravesical Gemcitabine and Docetaxel (Intravesical Gemcitabine and Docetaxel) — Michael A. O'Donnell.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Intravesical Gemcitabine and Docetaxel TARGET | Intravesical Gemcitabine and Docetaxel | Michael A. O'Donnell | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Intravesical Gemcitabine and Docetaxel CI watch — RSS
- Intravesical Gemcitabine and Docetaxel CI watch — Atom
- Intravesical Gemcitabine and Docetaxel CI watch — JSON
- Intravesical Gemcitabine and Docetaxel alone — RSS
Cite this brief
Drug Landscape (2026). Intravesical Gemcitabine and Docetaxel — Competitive Intelligence Brief. https://druglandscape.com/ci/intravesical-gemcitabine-and-docetaxel. Accessed 2026-05-18.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab